Burlingame, CA, United States of America

Madeleine Kieffer


 

 

Average Co-Inventor Count = 9.5

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022-2025

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: **Madeleine Kieffer: Innovator in Pharmaceutical Chemistry**

Introduction

Madeleine Kieffer, an accomplished inventor based in Burlingame, California, has made significant contributions to the field of pharmaceutical chemistry. With her innovative approach and dedication to research, she has been granted a patent that highlights her commitment to advancing medical science.

Latest Patents

Madeleine Kieffer holds a patent for her work on benzimidazole derivatives and their uses. The present invention focuses on inhibitors of Transient Receptor Potential Channel 6 (TRPC6) protein activity. The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, along with pharmaceutical compositions containing this compound, a method for manufacturing the compounds, and their therapeutic uses.

Career Highlights

Kieffer is currently employed at Teijin Pharma Limited, a prominent player in the pharmaceutical industry. Her work has not only contributed to the company's advancements but has also showcased her skills as an innovative thinker and problem solver in her field.

Collaborations

Throughout her career, Madeleine has worked closely with talented colleagues such as Michael D. Bartberger and Nagasree Chakka. These collaborations have further fostered an environment of creativity and innovation, leading to breakthroughs in pharmaceutical research.

Conclusion

Madeleine Kieffer's achievements in the realm of pharmaceutical chemistry exemplify the impact of innovation on public health. Her patented work on TRPC6 inhibitors exemplifies her commitment to creating new therapies that could potentially change the landscape of medical treatment. As she continues her work at Teijin Pharma Limited, her contributions will undoubtedly inspire future advancements in the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…